Knownwell Review

Knownwell — Provider Profile

Overview

Knownwell is a hybrid obesity medicine clinic operating in select Northeast markets, offering both in-person and virtual care. What sets Knownwell apart is clinical depth: the platform is staffed by board-certified obesity medicine physicians — a specialty designation that requires additional training beyond general internal medicine or family practice. That distinction matters in a market where most telehealth platforms assign GLP-1 prescriptions through general practitioners or nurse practitioners conducting asynchronous reviews.

Obesity medicine board certification (from the American Board of Obesity Medicine) signals that a physician has demonstrated competency in the pathophysiology of obesity, behavioral interventions, pharmacotherapy, and bariatric evaluation. For patients who have tried and failed previous weight management approaches, who have significant metabolic comorbidities, or who have experienced medication intolerances, that level of clinical expertise can meaningfully change outcomes. Knownwell's hybrid model — combining video visits with in-person appointments — also allows for physical examination when clinically warranted, something no asynchronous telehealth platform can provide.

Founded in 2022 and based in Boston, Knownwell currently serves a limited set of Northeast markets. Geographic availability is a real constraint, and patients outside those markets should confirm whether virtual-only access is available to them. The platform accepts insurance, which distinguishes it from the majority of direct-to-consumer GLP-1 telehealth platforms operating on a cash-pay model.

Medications Offered

• Wegovy (semaglutide, brand-name; FDA-approved for chronic weight management)
• Zepbound (tirzepatide, brand-name; FDA-approved for chronic weight management)
• Saxenda (liraglutide; available for patients who cannot tolerate weekly injectables)
• Compounded semaglutide and tirzepatide where clinically indicated and available
• Oral medications for weight management (phentermine, topiramate, metformin as adjunct)
• Qsymia, Contrave, and other FDA-approved anti-obesity agents per clinical assessment

Note on compounded medications (April 2026): Compounded semaglutide lost its FDA shortage exemption in February 2025. Compounded tirzepatide from 503A pharmacies faces an April 2026 FDA enforcement deadline. Knownwell's primary prescribing pathway for GLP-1 medications is brand-name, insurance-covered products, which reduces supply-chain exposure to compounding enforcement. Patients should confirm current formulary options during consultation.

Pricing

Verify current pricing, insurance panel, and out-of-pocket estimates at knownwell.com. Insurance coverage for GLP-1 medications varies significantly by plan; Knownwell's clinical team assists with prior authorization processes.

States Served

Knownwell currently operates in select Northeast markets with both in-person and virtual access. Virtual-only access may be available in additional states. Patients outside the primary service area should contact Knownwell directly to confirm eligibility. Geographic expansion is ongoing — availability as of April 2026 may differ from this profile's publication date.

Insurance

• Insurance accepted; participates with major commercial plans in active markets
• Prior authorization support provided for GLP-1 medications
• Medicare and Medicaid acceptance varies by location — confirm during intake
• FSA/HSA payment accepted for cash-pay portions
• Knownwell's clinical team assists with insurance navigation and appeals for denied prior authorizations

Consultation Process

Model: Hybrid video and in-person, physician-led

1. Intake questionnaire and insurance verification completed online
2. Initial appointment with obesity medicine-certified physician (video or in-person)
3. Lab work ordered or reviewed as part of initial assessment
4. Individualized treatment plan developed — medication, behavioral support, follow-up cadence
5. Ongoing visits per plan (typically monthly initially, then quarterly as appropriate)
6. In-person visits scheduled when physical examination, injection training, or clinical escalation is warranted

Pros

• Board-certified obesity medicine physicians provide a level of clinical specialization not available on most telehealth platforms
• Hybrid model allows in-person examination for complex cases, medication intolerance evaluation, and physical assessment
• Insurance-accepted model reduces out-of-pocket costs compared to cash-pay competitors
• Full GLP-1 formulary including brand-name Wegovy and Zepbound, insulating patients from compounding supply disruptions
• Prior authorization support included — meaningful given how frequently GLP-1 coverage is denied on first submission
• Appropriate for patients with significant comorbidities (T2D, hypertension, sleep apnea) who need specialist-level management

Cons

• Geographic availability is limited to select Northeast markets; not a national platform as of April 2026
• Insurance-based model means access depends on plan participation and prior authorization approval
• Not the fastest or cheapest path to a GLP-1 prescription for patients who simply want access and have no comorbidities
• In-person visit requirement (when clinically appropriate) is a barrier for patients who cannot travel to a clinic
• Limited public information on cash-pay pricing for patients without covered insurance

Best For

Patients with obesity and significant metabolic comorbidities (type 2 diabetes, cardiovascular risk factors, hypertension), prior treatment failures on other platforms, or medication intolerances who need specialist-level evaluation. Also appropriate for patients who prefer an insurance-covered care model and want a long-term clinical relationship rather than a transactional prescription platform. Patients in the Northeast who can access in-person visits get the fullest version of what Knownwell offers.

Editorial Verdict

Knownwell represents what obesity medicine care is supposed to look like — specialists who understand the disease, a care model that accommodates clinical complexity, and a reimbursement approach that doesn't require patients to pay out-of-pocket for every visit. For patients who have cycled through telehealth platforms without sustained results, or who have been told they're "too complex" for a standard GLP-1 protocol, Knownwell is worth prioritizing over faster, cheaper options.

The trade-off is access. Geographic constraints mean many patients cannot use Knownwell, and the insurance-dependent model introduces prior authorization friction that cash-pay platforms avoid by design. Patients with straightforward profiles who qualify easily for GLP-1 medications and have no significant comorbidities may find a simpler, faster path through other platforms.

For clinically complex patients in Knownwell's service area, however, the depth of care is difficult to match. The board-certification standard for their physicians is a meaningful differentiator, not a marketing claim, and the hybrid model's ability to incorporate physical examination when needed fills a genuine gap in telehealth obesity care.

Related Content

• Who Qualifies for GLP-1 Medications?
• How Much Does Semaglutide Cost?
• How Much Does Tirzepatide Cost?